Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomization was performed by a person who was not a study interviewer or therapist using a SAS procedure and was stratified by patient performance status (self-reported ECOG scores 0 or 1 vs. 2) because this factor informs cancer treatment decision-making [33].”
From Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial (2018) · cites this paper as [33]
In the citing paper
“We are stratifying randomization by performance status because it is a key factor in MBC treatment decisions [28].”
From Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer (2020) · cites this paper as [28]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Research works printed but not linked: 1
- Network NCC. 2008. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2, ASCO-Edition 2008.
Cited by
Items 301–400 of 485
Akbari, M. E., Akbari, A., Nafissi, N., Shormeij, Z., Sayad, S., Rohani-Rasaf, M., & Shojaee, L. (2016) · Iranian Journal of Cancer Prevention · doi:10.17795/ijcp-5747 · Cited by 7
Hwang, E., Uh, J., Lee, H. S., Lee, C. H., Lee, S., Ahn, S. H., Son, B. H., Lee, J. W., Yu, J. H., Kwon, N., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6077 · Cited by 7
Gonçalvès, A., Moretta, J., Eisinger, F., & Bertucci, F. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1856 · Cited by 12
From the Breast to the Bowel: An Unconventional Metastatic Presentation
Gangireddy, M., Shrimanker, I., Saintelia, S., Gomez, J. C., & Peroutka, K. A. (2019) · Cureus · doi:10.7759/cureus.6199 · Cited by 7
Li, W., Wang, H., & Li, X. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.832185 · Cited by 7
Mosher, C. E., Krueger, E., Hirsh, A. T., Miller, K. D., Ballinger, T. J., Storniolo, A. M., Schneider, B. P., Newton, E. V., Champion, V. L., & Johns, S. A. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106168 · Cited by 6
“We are stratifying randomization by performance status because it is a key factor in MBC treatment decisions [28].”
MethodZhang, W., Tan, Y., Huang, Z. K., Tan, Q., Zhang, Y., Chen, B., & Wei, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1409273 · Cited by 6
Bighin, C., Dozin, B., Poggio, F. B., Ceppi, M., Bruzzi, P., D’Alonzo, A., Levaggi, A., Giraudi, S., Lambertini, M., Miglietta, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14735 · Cited by 6
Wu, W., Zhang, H., Fang, Z., & Li, F. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4764 · Cited by 6
Pisano, C. E., Kharouta, M. Z., Harris, E. E. R., Shenk, R., & Lyons, J. A. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.04.002 · Cited by 6
Comprehensive Analysis of the Expression and Prognosis of chromobox Family Members in Breast Cancer
Wang, L., Zhao, L., Zhang, Y., Shao, S. H., Ning, Q., Zhao, X., & Luo, M. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.02.007 · Cited by 6
Abbreviated MRI for Comprehensive Regional Lymph Node Staging during Pre-Operative Breast MRI
Bode, M., Schrading, S., Masoumi, A., Morscheid, S., Schacht, S., Dirrichs, T., Gaisa, N. T., Stickeler, E., & Kuhl, C. K. (2023) · Cancers · doi:10.3390/cancers15061859 · Cited by 6
“Information on nodal disease is still a decisive factor to guide systemic treatment in particular in patients with ER-positive, HER-2 negative disease [22].”
BackgroundKoleva‐Kolarova, R., Vellekoop, H., Huygens, S. A., Versteegh, M., Mölken, M. R., Szilberhorn, L., Zelei, T., Nagy, B., Wordsworth, S., & Tsiachristas, A. (2023) · Personalized Medicine · doi:10.2217/pme-2022-0099 · Cited by 8
Lee, J., Kim, H. H., Ro, S. M., & Yang, J. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171605 · Cited by 8
Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
Pronzato, P. (2017) · Future Oncology · doi:10.2217/fon-2017-0098 · Cited by 6
Falato, C., Taylor, S. K., Szulkin, R., Nordblom, A., Eriksson, L., Sofiadis, A., Fredriksson, I., Hartman, J., Bergh, J. C. S., & Foukakis, T. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4936-2 · Cited by 6
Ayandipo, O. O., Adeleye, A. O., Ulasi, I. B., & Ogundiran, T. O. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.03.279 · Cited by 6
Taheri, M., Tavakol, M., Akbari, M. E., Anoushirvani, A. A., Aghabozorgi, R., Almasi‐Hashiani, A., & Abbasi, M. (2018) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2019.60.3.1162 · Cited by 6
Bochenek‐Cibor, J., Zawisza, K., Georgiew, F., & Bała, M. M. (2020) · Journal of Cancer Education · doi:10.1007/s13187-020-01760-y · Cited by 7
Zhu, Y., Li, K., Zhang, J., Wang, L., Sheng, L., & Liang, Y. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-1760 · Cited by 6
Comprehensive Review of Metastatic Breast Carcinoma in Cytology Specimens
Baskota, S. U., Qazi, D., Chandra, A., & Vohra, P. (2022) · Journal of Molecular Pathology · doi:10.3390/jmp3040025 · Cited by 7
Conversion of hormone and HER-2 receptor in metachronous neck metastases from breast carcinoma
Nauroth, A., Kalder, M., Rößler, M., Wichmann, G., Dietz, A., & Wiegand, S. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2426-2 · Cited by 6
“Since treatment strategies are affected by a change in receptor status the European Society for Medical Oncology guidelines recommend retesting of metastases for hormone receptors wherever possible (Cardoso et al. 2012).”
BackgroundIeni, A., Barresi, V., Giuffrè, G., Caltabiano, R., Cascone, A. M., SORDO, R. D., Cabibi, D., Zeppa, P., Lanzafame, S., Sidoni, A., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.013 · Cited by 6
A 66-year-old woman with spontaneous rib fracture
Harris, S. R. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141435 · Cited by 5
Morritti, M. G., Iodice, G., Melaccio, A., D’Onofrio, L., Bergnolo, P., Boglione, A., Comandone, A., Molinaro, P., & Garigliano, D. (2017) · Future Oncology · doi:10.2217/fon-2016-0529 · Cited by 5
Jafri, M., Kristeleit, H., Misra, V., Baxter, M. A., Ahmed, S. I., Jegannathen, A., Jain, A., Maskell, D., Barthakur, U., Edwards, G., et al. (2022) · Oncology · doi:10.1159/000526140 · Cited by 4
Ring, A. E., Karuturi, M. S., Smyth, E. N., Lokhandwala, T., Sheffield, K. M., Willey, J., Lunacsek, O., Sapunar, F. J., Cui, Z. L., Coutinho, A. D., et al. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00391-1 · Cited by 5
Deng, S., Zhang, W., Zhang, B., & Wu, Y. (2014) · PubMed Central · doi:10.3978/j.issn.1000-9604.2014.08.17 · Cited by 5
Harbeck, N., & Wuerstlein, R. (2013) · Drugs · doi:10.1007/s40265-013-0118-z · Cited by 5
Self-citationGüth, U., Huang, D. J., Schötzau, A., & Schmid, S. M. (2015) · Oncology · doi:10.1159/000439570 · Cited by 5
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
Taghizadeh, H., Zöchbauer‐Müller, S., Mader, R. M., Müllauer, L., Klikovits, T., Bachleitner‐Hofmann, T., Hoda, M. A., & Prager, G. W. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13491 · Cited by 5
Hani, M. B., Attuwaybi, B. O., & Butler, B. (2019) · International Surgery · doi:10.9738/intsurg-d-19-00009.1 · Cited by 5
Where does Radioimmunotherapy Fit in the Management of Breast Cancer?
Doddamane, I., Butler, R., Jhaveri, A. P., Chung, G. G., & Cheng, D. (2013) · Immunotherapy · doi:10.2217/imt.13.78 · Cited by 5
Relationship of the expression of circulating hsa-miR-125a-3p and hsa-miR-125b with breast cancer
Ramezani, S., Sasani, S. T., Fakor, F., & Alizadehsefat, S. (2019) · British Journal of Biomedical Science · doi:10.1080/09674845.2019.1674470 · Cited by 5
PRINCIPAIS TRATAMENTOS UTILIZADOS NO COMBATE AO CÂNCER DE MAMA: UMA REVISÃO DE LITERATURA
Nascimento, A. S., Mello, E. V. D. S. L., Schneider, L. C. L., & de Almeida, F. L. A. (2019) · Arquivos do Mudi · doi:10.4025/arqmudi.v23i3.51538 · Cited by 7
Üyetürk, Ü., Öksüzoğlu, B. Ç., Akman, T., Türker, İ., Sener, N. D., Taştekin, D., Bal, Ö., Berk, V., Arslan, Ü. Y., Urakçı, Z., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0929-0 · Cited by 5
De-implementing Low-Value Care in Cancer Care Delivery: A Systematic ReviewPreprint
Tabriz, A. A., Turner, K. L., Clary, A., Hong, Y., Nguyen, O. T., Wei, G., Carlson, R., & Birken, S. A. (2021) · Research Square · doi:10.21203/rs.3.rs-662637/v1 · Cited by 5
Brandstetter, L., Grau, A., Heuschmann, P. U., Müller-Reiter, M., Salmen, J., Störk, S., Wöckel, A., & Reese, J. (2025) · BMC Cancer · doi:10.1186/s12885-025-13548-8 · Cited by 5
Liu, S., Xie, Y., Ding, W., Ma, X., Li, Z., Zhang, L., Zhang, Y., & Ai, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1602415 · Cited by 5
Wang, X., Li, C., Li, C., Qin, M., Wu, J., Qin, Y., Zou, Y., Zeng, H., Li, C., Huang, X., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1600892 · Cited by 5
Clinical implications of first and multiple locoregional breast cancer recurrences
Wenners, A. S., Berlin, L., Alkatout, İ., van Mackelenbergh, M., Jonat, W., & Mundhenke, C. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3586-9 · Cited by 4
Espié, M., Moley-Massol, I., Zernik, N., Debiais, D., & Dieras, V. C. (2018) · ONCOLOGIE · doi:10.3166/onco-2018-0013 · Cited by 4
Dhanota, N., Bal, A., Singh, G., & Arora, S. K. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202105.008 · Cited by 5
Lin, P. L., Hao, Y., Xie, J., Li, N., Ohashi, E., Koo, V., & Wu, E. Q. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1074182 · Cited by 4
Reis, F. P., Santos, M. E. G., Sena, W. D. R., Santana, R., Freitas, T. S. D., da Silveira, H. F., & Ribeiro, H. L. (2016) · Revista de Ciências Médicas e Biológicas · doi:10.9771/2236-5222cmbio.v15i2.15194 · Cited by 4
Koumarianou, A. A., Makrantonakis, P., Zagouri, F., PAPADIMITRIOU, C. A., Christopoulou, A. N., Samantas, E., Christodoulou, C., Psyrri, A. K., Bafaloukos, D. I., Aravantinos, G., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05677-4 · Cited by 4
Page, R. L., Patil, D., Akolkar, D. B., Murthy, S., Bendale, K., Patil, R., Fulmali, P., Fulmali, P., Adhav, A., Puranik, S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270139 · Cited by 3
Comprehensive analysis identifies as a critical prognostic prediction gene in breast cancer
Hu, T., Wang, X., Xia, Y. F., Wu, L., Ma, Y., Zhou, R., & Zhao, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002025 · Cited by 4
“Despite great advances in classic clinical biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2),([2]) which play a critical role in helping to judge the prognosis and drug sensitivity of BC,([3,4]) the prognosis in these patients remains poor.([5])…”
BackgroundJu, G., Zhu, R., Zhao, H., Ye, F., Zhang, L., Lin, C., Lu, Y., Zhang, X., Li, N., Xue, P., et al. (2018) · Europe PMC (PubMed Central) · Cited by 6
Yu, C., Kuo, W.-L., Shen, S., Chou, H., Lo, Y., Yu, M., & Chen, S. (2020) · Biomedical Journal · doi:10.1016/j.bj.2019.07.002 · Cited by 4
Li, N., Hao, Y., Koo, V., Fang, A., Peeples, M., Kageleiry, A., Wu, E. Q., & Guérin, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2015.1131704 · Cited by 4
Kalsoom, M., Rehman, H. M., Al‐Qassab, Y., Rehman, H. M., Syed, R., Ahmed, N., Wu, Y., Al-Qahtani, A. A., Nadeem, T., & Bashir, H. (2025) · Toxicology Research · doi:10.1093/toxres/tfaf060 · Cited by 3
Utility of FDG PET/CT in Patient with Synchronous Breast and Colon Cancer
Su, I.-L., & Chen, Y. (2023) · Diagnostics · doi:10.3390/diagnostics13132293 · Cited by 3
“At the time of diagnosis, approximately 5% to 10% of patients will harbor lymph nodes or distant metastases [7].”
Restoration of A2M reduces drug resistance and malignancy in paclitaxel-resistant lung cancer cells
Fan, X., Xue, H., Liu, Z., Zhou, Y., Huang, X., Dong, X., Sun, Q., Yao, J., & Liu, J. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106789 · Cited by 3
Liang, C., Yang, C., Yang, Q., Tang, Y., Zhang, W., Tan, Q., & Qin, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1598069 · Cited by 4
Die Rolle der Viszeralchirurgie bei Oligometastasierung nichtgastrointestinaler Tumoren
Wahba, R., Stippel, D. L., & Bruns, C. J. (2018) · Der Chirurg · doi:10.1007/s00104-018-0647-9 · Cited by 3
Arıcı, S., Hamdard, J., Sakin, A., Erhan, S. Ş., Atçı, M. M., Çekin, R., Saka, B., Köse, E., Saydam, T., Geredeli, Ç., et al. (2020) · Colorectal Disease · doi:10.1111/codi.15389 · Cited by 3
Zhang, S., Yang, H., Xu, Y., & Wang, S. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07340-8 · Cited by 3
“These findings underscore the rationale for considering a new round of ‘pseudo-adjuvant’ approach to con-trol the death risk of IBTR, as suggested by the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines [9, 26].”
DNA damage targeted therapy for advanced breast cancer
Patel, V., Casimiro, S., Abreu, C., Barroso, T., Sousa, R., Torres, S., Ribeiro, L., Nogueira-Costa, G., Pais, H. L., Pinto, C., et al. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00241 · Cited by 4
Wang, K., Shen, L., Chen, Y., & Tang, Z. (2024) · BioMedical Engineering OnLine · doi:10.1186/s12938-024-01274-4 · Cited by 3
“For women with breast cancer who have developed metastatic disease, systemic therapy (ST) is the primary therapeutic approach and chemotherapy has been recommended in the guideline [22].”
BackgroundTherapy of isolated locoregional recurrent carcinoma of the breast
Gabriel, L., Schmidt, M., Juhasz-Böss, S., Melchior, P., von Heesen, A., Schmidt, G., Kranzhöfer, N., Solomayer, E., Juhasz-Böss, I., & Breitbach, G. P. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05220-x · Cited by 3
Yao, J., Zhang, W., Shao, Y., Zhu, Y., Liu, J., Jin, G., & Yang, Y. (2020) · PubMed Central · Cited by 3
Systemic Therapy of Bone Metastases
Kamposioras, K. V., & Briasoulis, E. C. (2013) · Cancer metastasis · doi:10.1007/978-94-007-7569-5_13 · Cited by 3
Case Studies in the Management of Metastatic Breast Cancer with Eribulin
Wilks, S. T., & McIntyre, K. J. (2015) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s27962 · Cited by 3
New Insights into Endocrine Therapy for Young Women with Breast Cancer
Lascio, S. D., & Pagani, O. (2015) · Women s Health · doi:10.2217/whe.15.2 · Cited by 4
Etirinotecan pegol for the treatment of breast cancer
López-Miranda, E., & Cortés, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154537 · Cited by 3
Defining the Influence of Germline Variation on Metastasis Using Systems Genetics Approaches
Lee, M., & Crawford, N. P. S. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.003 · Cited by 4
Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management
Senkus, E., & Łacko, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_49 · Cited by 3
Self-citationBilici, A. E., Uysal, M., Menekşe, S., Akin, S., Yıldız, F., Turan, M., Göksu, S. S., Beypınar, İ., Şakalar, T., Değirmenci, M., et al. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.2017952 · Cited by 4
Comprehensive Analysis of the Expression and Prognostic Significance of THBSs in Breast CancerPreprint
Wang, J., Zhan, X., Luo, Q., Kuang, Y., Liang, X. M., Wang, J., Tao, X., Sun, E., & Chen, B. (2021) · Research Square · doi:10.21203/rs.3.rs-620437/v1 · Cited by 3
An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ
Byng, D., Schaapveld, M., Lips, E. H., van Duijnhoven, F. H., Wesseling, J., van Harten, W. H., & Retèl, V. P. (2024) · Future Oncology · doi:10.1080/14796694.2024.2421152 · Cited by 2
Green synthesis and in vitro anticancer evaluation of 1,2-disubstituted benzimidazole derivatives
Avila‐Sorrosa, A., Gil-Ruiz, L. Á., Vargas-Díaz, M. E., Torres-Nogueda, B., & Morales‐Morales, D. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102134 · Cited by 4
Paiano, L., Adam, R. A., & Golse, N. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102330 · Cited by 3
Extra-mammary findings on breast MRI: a pictorial review
Karp, N. L., Price, E. R., Wisner, D. J., Chang, C.-J., Hylton, N. M., & Joe, B. N. (2015) · Clinical Imaging · doi:10.1016/j.clinimag.2015.01.019 · Cited by 2
HER Receptor, Current, and Emerging Therapeutic Targets
Tan, M., Yeap, J. W., & Matawali, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_258-1 · Cited by 4
Şahin, E. (2023) · Open Access Journal of Oncology and Medicine · doi:10.32474/oajom.2023.05.000215 · Cited by 1
Hao, Y., Lin, P. L., Xie, J., Li, N., Koo, V., Ohashi, E., Wu, E. Q., & Rogerio, J. W. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.25 · Cited by 2
Estado del arte el diagnóstico y tratamiento del cáncer de mama
Torres, C. S., Acevedo, B. J. C., Aguirre, D. B., Aliaga, M. N., Cereceda, G. L., Dagnino, U. B., Gutiérrez, C. J., Ibarra, V., Paredes, F. H., Miguel, R. V. J., et al. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70199-8 · Cited by 12
Pathology-Confirmed Granuloma Mimicking Liver Metastasis of Breast Cancer
Li, T., Fan, M., Shui, R., Hu, S., Zhang, Y., & Hu, X. (2014) · The International Journal of Biological Markers · doi:10.5301/jbm.5000074 · Cited by 2
Tang, D. H., Li, N., Du, E. X., Peeples, M., Chu, L.-H., Xie, J., & Barghout, V. E. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1390447 · Cited by 2
Velikaya, V. V., Старцева, Ж. А., Lisin, V. A., Goldberg, V. E., & Popova, N. O. (2022) · Medical Radiology and radiation safety · doi:10.33266/1024-6177-2022-67-5-64-68 · Cited by 2
Single Jejunum Metastasis from Breast Cancer Arising Twelve Years after the Initial Treatment
Paiva, C., Garcia, J. P., Silva, A. C., Araújo, A., Araújo, A., & Santos, M. D. (2016) · Case Reports in Oncological Medicine · doi:10.1155/2016/8594652 · Cited by 2
Shee, K., Wells, J. D., Ung, M. H., Hampsch, R. A., Traphagen, N. A., Yang, W., Liu, S. C., Zeldenrust, M. A., Wang, L., Kalari, K. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2213 · Cited by 3
Nab-paclitaxel in Treatment of Metastatic Breast Cancer
Kovalenko, E. I., & Артамонова, Е. В. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-2-17(392)-12-18 · Cited by 2
“лениями оптимальной стратегией, подходящей для большинства пациенток, является последовательное назначение монорежимов [2].”
Alarfi, H., Youssef, L. A., & Salamoon, M. (2020) · doi:10.21203/rs.2.16886/v2 · Cited by 3
Ghiga, I., d'Angelo, C., King, S., Exley, J., Harshfield, A., Rodriguez-Rincon, D., Leach, B., Manville, C. M., & Marjanovic, S. (2019) · RAND Corporation eBooks · doi:10.7249/rr3010.2 · Cited by 1
Khan, N. A., Nguyen, S., Teh, P., Ranpura, V. N., & Bhatia, T. (2021) · The Permanente Journal · doi:10.7812/tpp/20.244 · Cited by 1
Wang, B.-Q., Fang, X.-G., Xiang, B.-H., Wang, X., Cao, M., Zhuang, C.-L., Liu, Z.-C., & Wang, Z. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.103328 · Cited by 2
Prognostic model for predicting recurrence in breast cancer patients in Saudi Arabia
Khan, O., Ajadi, J. O., Almsned, F. M., Almohanna, H., Alrasheed, A., Sanusi, R. A., & Adegoke, N. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-94530-z · Cited by 2
“Recurrence was determined through routine follow-up assessments including clinical evaluations and laboratory investigations 15 .”
Determinants of delay in presentation to completion of treatment in cervical cancer
Begum, D., Bassetty, K. C., Barmon, D., Baruah, U., Nath, J., Khanikar, D., Roy, P. S., Bhattacharyya, M., Ahmed, S., Kumar, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-25103-3 · Cited by 1
Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases
Li, S., Xie, Y., Liu, C., Song, S., Wang, H., Yang, Z., & Wang, B. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07657-6 · Cited by 1
Li, Z., Zhong, J., Shi, Y., Lu, W., Lu, Y., & Ge, N. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1694960 · Cited by 1
Surgical possibilities in the treatment of advanced and locally recurrent breast cancers
Mátrai, Z., & Vámos, F. R. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29891 · Cited by 1
Scott, L. J., Croxtall, J. D., & McKeage, K. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0098-9 · Cited by 1
Breast Magnetic Resonance Imaging Incidental Findings
Szabo, J. R. (2014) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000036 · Cited by 1
Alotaibi, N., Alosaimy, R., & Mushaddak, W. (2019) · International Journal of Medicine in Developing Countries · doi:10.24911/ijmdc.51-1555003245 · Cited by 1
Prediction of Caesarean Delivery
Murphy, N. C., Breathnach, F., & Burke, N. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87311 · Cited by 1
(2022) · European Journal of Gynaecological Oncology · doi:10.31083/j.ejgo4302029 · Cited by 1
Impacto das principais formas de tratamentos na qualidade de vida de pacientes com câncer de mama
Aguiar, R. D. C. S., Freitas, E. C. B. F., & Freitas, M. T. D. S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i8.30450 · Cited by 1
Wu, F., Chen, M., Li, N., Wu, X., Huang, W., Chen, X., Chen, K., Wang, L., & Liu, J. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2107753 · Cited by 1
“Heavily pretreated ( 3-line treatment) metastatic breast cancer (MBC) patients were genetically heterogeneous disease and lack of prognostic or predictive biomarker to guide tailored treatment [1,2].”
Background
Metadata
- Authors
- Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E.
- Affiliations
- European School of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Gdańsk Medical University (PL)
- Corresponding author
- Senkus, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 23
- Pages
- vii11-vii19
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4234749243
- Cited by
- 485
- References
- 40
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 30 · 2020: 37 · 2019: 41 · 2018: 33 · 2017: 53 · 2016: 42 · 2015: 66 · 2014: 49 · 2013: 32 · 2012: 1
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2625 d)
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- locally recurrent breast cancer, metastatic breast cancer, breast cancer diagnosis, breast cancer treatment, breast cancer follow-up, incidence, mortality, early detection, adjuvant systemic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.